From: Urinary DNA methylation biomarkers for prediction of prostate cancer upgrading and upstaging
Parameter | Upstaging | Upgrading | Risk change | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Sensitivity, % | Specificity, % | PPV, % | NPV, % | Sensitivity, % | Specificity, % | PPV, % | NPV, % | Sensitivity, % | Specificity, % | PPV, % | NPV, % | |
Voided urine (N = 188) | ||||||||||||
PSA | 86.7 | 27.9 | 23.4 | 89.1 | 82.6 | 27.0 | 29.7 | 80.6 | 85.0 | 27.4 | 26.9 | 85.3 |
RARB, RASSF1, GSTP1 | 52.3 | 72.5 | 32.6 | 85.6 | 50.7 | 67.5 | 36.9 | 78.6 | 45.8 | 71.3 | 33.4 | 80.7 |
RARB, RASSF1, GSTP1+PSA | 56.8 | 65.2 | 29.4 | 85.6 | 47.8 | 74.6 | 41.2 | 79.3 | 89.8 | 27.0 | 27.9 | 89.4 |
RASSF1, GSTP1 | 50.0 | 73.9 | 32.8 | 85.3 | 50.7 | 69.3 | 35.7 | 78.1 | 45.8 | 71.3 | 33.4 | 80.7 |
RASSF1, GSTP1+PSA | 54.5 | 66.7 | 27.7 | 84.6 | 40.3 | 81.6 | 45.0 | 78.5 | 89.8 | 27.0 | 27.9 | 89.4 |
Catheterized urine (N = 326) | ||||||||||||
PSA | 73.1 | 51.4 | 27.7 | 88.2 | 66.1 | 64.8 | 41.2 | 87.3 | 58.2 | 62.6 | 32.8 | 82.7 |
RARB, RASSF1, GSTP1 | 68.7 | 43.7 | 23.7 | 84.6 | 63.8 | 54.8 | 34.5 | 80.2 | 30.2 | 82.4 | 35.0 | 79.0 |
RARB, RASSF1, GSTP1+PSA | 60.9 | 63.3 | 29.7 | 86.4 | 56,9 | 79,2 | 50.5 | 83.1 | 56.6 | 62.1 | 31.2 | 81.4 |
RASSF1, GSTP1 | 67.2 | 53.9 | 27.1 | 86.6 | 84.5 | 3.6 | 24.7 | 38.4 | 35.8 | 75.8 | 31.7 | 79.0 |
RASSF1, GSTP1+PSA | 65.6 | 64.9 | 27.5 | 86.5 | 55.2 | 80.5 | 51.4 | 82.8 | 58.5 | 61.2 | 32.2 | 82.4 |